|
Number of patients
|
36
|
108
| |
|
Duration of uninterrupted meropenem use, days, median (IQR)
|
34 (31–39)
|
9 (7–11)
|
<0.001
|
|
Age in years, median (IQR)
|
63 (51–71)
|
66 (56–73)
|
0.26
|
|
Female sex, n (%)
|
13 (36.1)
|
36 (33.3)
|
0.76
|
|
Days on ICU, median (IQR)
|
66 (51.5–92.5)
|
35 (31–45)
|
<0.001
|
|
Malignancy, n (% of all pts)
|
17 (47.2)
|
22 (20.4)
|
0.002
|
|
SAPS score at admission, median (IQR)
|
42 (35–48)
|
39 (33–47)
|
0.36
|
|
Medical patients, n (% of all pts)
|
4 (11.1)
|
45 (42.7)
|
0.001
|
|
Neurological patients, n (% of all pts)
|
6 (16.7)
|
30 (26.9)
|
0.22
|
|
Surgical patients, n (% of all pts)
|
26 (72.2)
|
34 (31.5)
|
<0.001
|
|
Number of operations, median (IQR)c
|
14 (5–27)
|
4 (3–7)
|
<0.001
|
|
Colonization/infection with carbapenem-susceptible, multidrug-resistant Enterobacteriaceae n (%)
|
7 (19.4)
|
7 (6.5)
|
0.007
|
|
Type of infection, n (%)
|
|
pneumonia
|
4 (11.1)
|
27 (25.0)
|
<0.001
|
|
peritonitis
|
16 (44.4)
|
5 (4.6)
|
|
mediastinitis
|
6 (16.7)
|
4 (3.7)
|
|
unclear focus
|
10 (27.8)
|
72 (66.7)
|
|
In-ICU-mortality, n (%)
|
16 (44.4%)
|
27 (25.0%)
|
0.03
|
